Diamyd Medical announces update regarding interim CFO
Diamyd Medical today announces that Anna Styrud, appointed interim CFO in Diamyd Medical, will not be able to start her position as previously communicated due to changes in her availability. A review to find a new successor to the CFO position has begun. About Diamyd MedicalDiamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The Company’s investigational drug candidate retogatein, based on recombinant GAD65, was evaluated in the Phase 3 DIAGNODE-3 trial in recent-onset type 1 diabetes. The